Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery
Sponsor: Northwestern University
Summary
The purpose of this study is to determine if the addition of bupivacaine HCl injections will improve pain control after skin surgery. This is a randomized clinical trial. Approximately 100 participants will be randomized to receive either bupivacaine HCl or saline injections to help with the postsurgical pain. Patients will be provided with a take-home journal to complete indicating when and how much pain medication they required for the 3 days immediately following surgery. Participants will return the journal in-person at a follow up visit 7-21 days post-op. This study was a pilot study designed to determine the feasibility of this procedure. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be invited and considered for enrollment.
Official title: Locally Administered Bupivacaine Hydrochloride for Post-operative Pain Control in Cutaneous Surgery: a Randomized Controlled Trial
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-01-24
Completion Date
2025-06
Last Updated
2025-01-31
Healthy Volunteers
Yes
Conditions
Interventions
Bupivacaine Hydrochloride
Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
Saline
Normal saline injections.
Locations (1)
Northwestern University Department of Dermatology
Chicago, Illinois, United States